Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Translational Oncology
Erschienen in: Clinical and Translational Oncology 3/2015

01.03.2015 | Educational Series – Blue Series

Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics

verfasst von: J. Fang, Q. Xu

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Several cancers tend to metastasize to bone, leading to osteolytic or osteoblastic bone lesions. The respective phenotypes of bone destruction and bone formation vary in clinical features, including incidence, prognosis, skeletal-related events and bone biomarkers. In addition, different molecular mechanisms explain the difference in phenotype. For example, molecules involved in osteolytic bone metastases (represented with breast cancer) include parathyroid hormone-related protein, transforming growth factor-β, while in osteoblastic lesions (represented with prostate cancer), endothelin-1 and morphogenetic proteins, etc. play a more important role in bone formation. It is important for us to understand the differences of bone metastases between two phenotypes to help clinicians to understand the underlying mechanisms, behaviors and therapies in development and currently available for bone metastases.
Literatur
1.
2.
Mundy GR. Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93.CrossRefPubMed
3.
Guise T. Examining the metastatic niche: targeting the microenvironment. Semin Oncol. 2010;37(2):S2–14.CrossRefPubMed
4.
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20):6243s–9s.CrossRefPubMed
5.
Kataoka M, Kunisada T, Tanaka M, Takeda K, Itani S, Sugimoto Y, et al. Statistical analysis of prognostic factors for survival in patients with spinal metastases. Acta Med Okayama. 2012;66(3):213–9.PubMed
6.
Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastases. Mol Cancer Ther. 2007;6:2609–17.CrossRefPubMed
7.
Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113(1):193–201.CrossRefPubMed
8.
Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 2008;466(3):729–36.PubMedCentralCrossRefPubMed
9.
Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S. Predictors of survival in patients with prostate cancer and spinal metastases. J Neurosurg Spine. 2010;13(6):789–94.CrossRefPubMed
10.
Yavas O, Hayran M, Ozisik Y. Factors affecting survival in breast cancer patients following bone metastases. Tumori. 2007;93(6):580–6.PubMed
11.
12.
Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008;34(7):629–39.PubMedCentralCrossRefPubMed
13.
Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23(22):4925–35.CrossRefPubMed
14.
Saad F, Lipton A. Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. Curr Opin Support Palliat Care. 2010;4(3):127–34.CrossRefPubMed
15.
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97(1):59–69.CrossRefPubMed
16.
Ortiz A, Lin SH. Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum? Recent Results Cancer Res. 2012;192:225–33.CrossRefPubMed
17.
Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res. 2003;415:S67–74.CrossRefPubMed
18.
Granchi S, Brocchi S, Bonaccorsi L, Baldi E, Vinci MC, Forti G, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate. 2001;49:267–77.CrossRefPubMed
19.
Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastases. Expert Rev Mol Med. 2008;10:e7.CrossRefPubMed
20.
Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD Jr, et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol. 2007;21:486–98.PubMedCentralCrossRefPubMed
21.
Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996;56:663–8.PubMed
22.
Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110–6.CrossRefPubMed
23.
Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA. 2003;100:10954–9.PubMedCentralCrossRefPubMed
24.
Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113:2478–87.PubMedCentralCrossRefPubMed
25.
James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int. 2010;106(7):966–73.CrossRefPubMed
26.
Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer. 2012;118(22):5709–18.CrossRefPubMed
27.
Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013;31(14):1740–7.CrossRefPubMed
28.
Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8:739–50.CrossRefPubMed
29.
Zi X, Guo Y, Simoneau AR, Hope C, Xie J, Holcombe RF, et al. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res. 2005;65(21):9762–70.CrossRefPubMed
30.
Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood. 2008;112:196–207.PubMedCentralCrossRefPubMed
31.
Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005;65:7554–60.PubMed
32.
33.
Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, et al. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastases and inhibited bone formation in osteoblastic bone metastases. Prostate. 2011;71(6):615–25.PubMedCentralCrossRefPubMed
34.
Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clézardin P, et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer. 2007;97:964–70.PubMedCentralPubMed
35.
Schluter KD, Katzer C, Piper HM. An N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. Br J Pharmacol. 2001;132:427–32.PubMedCentralCrossRefPubMed
36.
Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12(Suppl 20):6213s–6s.CrossRefPubMed
37.
Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res. 1993;8(Suppl 2):S565–72.
38.
Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, et al. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer. 1998;78:1219–23.PubMedCentralCrossRefPubMed
39.
Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone. 2006;38:154–66.CrossRefPubMed
40.
Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res. 2004;64:994–9.CrossRefPubMed
41.
Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res. 2011;71(15):5194–203.PubMedCentralCrossRefPubMed
42.
Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res. 2004;64(22):8276–84.CrossRefPubMed
43.
Virk MS, Alaee F, Petrigliano FA, Sugiyama O, Chatziioannou AF, Stout D, et al. Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion. Bone. 2011;48(3):578–87.PubMedCentralCrossRefPubMed
44.
Mehrotra M, Krane SM, Walters K, Pilbeam C. Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. J Cell Biochem. 2004;93:741–52.CrossRefPubMed
45.
Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, et al. Tumor derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway. Cancer Res. 2005;65:11001–9.CrossRefPubMed
46.
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, et al. A multigenic program mediating breast cancer metastases to bone. Cancer Cell. 2003;3:537–49.CrossRefPubMed
47.
Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer. 1997;80(8 Suppl):1572–80.CrossRefPubMed
48.
Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996;98:1544–9.PubMedCentralCrossRefPubMed
49.
Falzon M, Du P. Enhanced growth of MCF-7 breast cancer cells overexpressing parathyroid hormone-related peptide. Endocrinology. 2000;141:1882–92.PubMed
50.
Isowa S, Shimo T, Ibaragi S, Kurio N, Okui T, Matsubara K, et al. PTHrP regulates angiogenesis and bone resorption via VEGF expression. Anticancer Res. 2010;30(7):2755–67.PubMed
51.
Linforth R, Anderson N, Hoey R, Nolan T, Downey S, Brady G, et al. Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. Clin Cancer Res. 2002;8:3172–7.PubMed
52.
Henderson MA, Danks JA, Slavin JL, Byrnes GB, Choong PF, Spillane JB, et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res. 2006;66:2250–6.CrossRefPubMed
53.
Saito H, Tsunenari T, Onuma E, Sato K, Ogata E, Yamada-Okabe H. Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastases of human breast cancer cells derived from MDA-MB-231. Anticancer Res. 2005;25(6B):3817–23.PubMed
54.
Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem. 2002;277:24571–8.CrossRefPubMed
55.
Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O’Connor-McCourt MD, et al. Transforming growth factor-β1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene. 2008;28(7):1005–15.CrossRefPubMed
56.
57.
Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastases of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011;19(2):192–205.PubMedCentralCrossRefPubMed
58.
Hiraga T, Yoneda T. Stimulation of cyclooxygenase-2 expression by TGF-b enhances bone metastases in breast cancer. J Bone Miner Res. 2004;19:S129.
59.
Ohshiba T, Miyaura C, Ito A. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastases. Biochem Biophys Res Commun. 2003;300:957–64.CrossRefPubMed
60.
61.
Maroni P, Matteucci E, Luzzati A, Perrucchini G, Bendinelli P, Desiderio MA. Nuclear co-localization and functional interaction of COX-2 and HIF-1α characterize bone metastases of human breast carcinoma. Breast Cancer Res Treat. 2011;129(2):433–50.CrossRefPubMed
62.
Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 2007;67(9):4157–63.CrossRefPubMed
63.
McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem. 2006;281(34):24171–81.CrossRefPubMed
64.
Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999;103:197–206.PubMedCentralCrossRefPubMed
65.
Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, et al. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastases. Mol Cancer. 2010;9:122.PubMedCentralCrossRefPubMed
66.
Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z, et al. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1. J Natl Cancer Inst. 2013;105(1):47–58.CrossRefPubMed
67.
68.
69.
Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464–72.CrossRefPubMed
70.
Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19(3):420–32.CrossRefPubMed
71.
Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314–21.CrossRefPubMed
72.
Winter MC, Coleman RE. Bisphosphonates in the adjuvant treatment of breast cancer. Clin Oncol. 2013;25(2):135–45.CrossRef
73.
Nuzzo F, Gallo C, Lastoria S, Di Maio M, Piccirillo MC, Gravina A, et al. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. Ann Oncol. 2012;23(8):2027–33.CrossRefPubMed
74.
Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor–associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012;12(1):40–8.CrossRefPubMed
75.
Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (national surgical adjuvant breast and bowel project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734–42.CrossRefPubMed
76.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.CrossRefPubMed
77.
Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21(23):4277–84.CrossRefPubMed
78.
Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009;10(9):872–6.PubMedCentralCrossRefPubMed
79.
Palmieri C, Fullarton JR, Brown J. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clin Cancer Res. 2013;19(24):6863–72.CrossRefPubMed
80.
Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679–87.CrossRefPubMed
81.
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082–92.CrossRefPubMed
Metadaten
Titel
Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics
verfasst von
J. Fang
Q. Xu
Publikationsdatum
01.03.2015
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 3/2015
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1247-x

Weitere Artikel der Ausgabe 3/2015

Clinical and Translational Oncology 3/2015 Zur Ausgabe

Research Article

Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification

Research Article

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies

Review Article

Appendiceal carcinoid tumor in children: implications for less radical surgery?

Review Article

Running away from side effects: physical exercise as a complementary intervention for breast cancer patients

Research Article

Expression and clinical significance of IMP3 in microdissected premalignant and malignant pancreatic lesions

Research Article

Multidisciplinary cancer care may impact on the postoperative mortality and survival of patients with oesophageal and oesophagogastric junction cancer: a retrospective cohort study

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Müde im Alter? Auch an die Nebenniere denken
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen